Dicerna Pharmaceuticals Logo

Email this page: News Release

FDA Grants Orphan Drug Designation for DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

For security reasons, registration is required before you can use this feature.
* Indicates required field